Rivastigmine

[1]  R. Polinsky,et al.  Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. , 1998, Clinical therapeutics.

[2]  R. Mohs,et al.  Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.

[3]  R. Polinsky,et al.  Dose‐dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease , 1998, Acta neurologica Scandinavica.

[4]  E. Shohami,et al.  Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat , 1998, Brain Research.

[5]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[6]  M. Mesulam,et al.  Butyrylcholinesterase in the life cycle of amyloid plaques , 1997, Annals of neurology.

[7]  M. Tuszynski,et al.  A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease , 1996, Neurology.

[8]  M. Groccia,et al.  Long-term tacrine treatment in patients with Alzheimer's disease , 1996, The Lancet.

[9]  M. Crismon,et al.  Effectiveness and Safety of Velnacrine for the Treatment of Alzheimer's Disease: A Double-blind, Placebo-Controlled Study , 1995 .

[10]  P. Antuono.  Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. , 1995, Archives of internal medicine.

[11]  S. Ibayashi,et al.  Inhibition of Acetylcholinesterase Modulates the Autoregulation of Cerebral Blood Flow and Attenuates Ischemic Brain Metabolism in Hypertensive Rats , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  S. Eagger,et al.  Tacrine and other anticholinesterase drugs in dementia , 1995 .

[13]  M. Takeda,et al.  Effects of SDZ ENA 713, novel acetyl cholinesterase inhibitor, on learning of rats with basal forebrain lesions , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[14]  K. Tanaka,et al.  Chronic administration of acetylcholinesterase inhibitor in the senescent Rat brain , 1994, Neurobiology of Aging.

[15]  Gastone G. Celesia,et al.  A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .

[16]  P. Solomon,et al.  A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. , 1994, JAMA.

[17]  K. Davis,et al.  A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. , 1994, The American journal of psychiatry.

[18]  P. Lamy.  The Role of Cholinesterase Inhibitors in Alzheimer’s Disease , 1994 .

[19]  H. Hirata,et al.  Effects of the acetylcholinesterase inhibitor ENA-713 on ischemia-induced changes in acetylcholine and aromatic amine levels in the gerbil brain. , 1993, Archives internationales de pharmacodynamie et de therapie.

[20]  A. Enz,et al.  Pharmacologic and Clinicopharmacologic Properties of SDZ ENA 713, a Centrally Selective Acetylcholinesterase Inhibitor , 1991, Annals of the New York Academy of Sciences.

[21]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[22]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[23]  S H Ferris,et al.  Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. , 1997, Alzheimer disease and associated disorders.

[24]  P. Mecocci,et al.  Cognitive enhancement therapy for Alzheimer's disease. The way forward. , 1997, Drugs.

[25]  S Shimohama,et al.  Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. , 1997, Alzheimer disease and associated disorders.

[26]  A. Lawrence,et al.  Alzheimer disease, attention, and the cholinergic system. , 1995, Alzheimer disease and associated disorders.

[27]  M. Chorev,et al.  Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. , 1994, Journal of neural transmission. Supplementum.

[28]  U. Hemmeter,et al.  Effects of the Novel Acetylcholinesterase Inhibitor SDZ ENA 713 on Sleep in Man , 1993, Neuropsychopharmacology.

[29]  H. Boddeke,et al.  Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. , 1993, Progress in brain research.